XNCR Insider Trading

Insider Ownership Percentage: 5.23%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,943,156.04

Xencor Insider Trading History Chart

This chart shows the insider buying and selling history at Xencor by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Xencor Share Price & Price History

Current Price: $9.73
Price Change: Price Increase of +0.04 (0.41%)
As of 04/2/2025 03:39 PM ET

This chart shows the closing price history over time for XNCR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$9.69Closing price on 04/01/25:

SEC Filings (Institutional Ownership Changes) for Xencor (NASDAQ:XNCR)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XNCR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$72Mbought$29MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Xencor logo
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Read More on Xencor

Today's Range

Now: $9.73
Low: $9.52
High: $10.02

50 Day Range

MA: $15.18
Low: $9.69
High: $20.67

52 Week Range

Now: $9.73
Low: $9.52
High: $27.24

Volume

368,918 shs

Average Volume

626,107 shs

Market Capitalization

$685.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Who are the company insiders with the largest holdings of Xencor?

Xencor's top insider investors include:
  1. Bassil I Dahiyat (CEO)
  2. John R Desjarlais (VP)
  3. John J Kuch (CFO)
  4. Celia Eckert (SVP)
  5. Alan Bruce Montgomery (Director)
  6. Kurt A Gustafson (Director)
Learn More about top insider investors at Xencor.